PHILADELPHIA, Aug. 24,
2023 /PRNewswire/ -- Carisma Therapeutics Inc.
(Nasdaq: CARM) ("Carisma" or the "Company"), a clinical stage
biopharmaceutical company focused on discovering and developing
innovative immunotherapies, today announced that the Company will
present at two healthcare industry conferences in September 2023. These conferences include:
8th Annual CAR-TCR Summit
- Michael Klichinsky, PharmD, PhD,
Co-Founder and Chief Scientific Officer, will give a presentation
during the summit.
-
- "CAR-M: Pioneering a Novel Approach for Solid Tumor
Immunotherapy"
-
- Friday, September 1, 2023 at
9:20 am ET
- Boston, Massachusetts
CAR-T Consortia Seminar
- Michael Klichinsky, PharmD, PhD,
Co-Founder and Chief Scientific Officer, will give a presentation
during the meeting.
-
- "CAR Macrophages"
-
- Tuesday, September 19, 2023 at
12:00 pm ET
- Virtual
A replay of webcasts, when available, will be posted and
archived at Carisma's Investor Events webpage for a limited time
following the event.
About Carisma Therapeutics
Carisma Therapeutics Inc. is a clinical stage biopharmaceutical
company focused on utilizing our proprietary macrophage and
monocyte cell engineering platform to develop transformative
immunotherapies to treat cancer and other serious diseases. We have
created a comprehensive, differentiated proprietary cell therapy
platform focused on engineered macrophages and monocytes, cells
that play a crucial role in both the innate and adaptive immune
response. Carisma is headquartered in Philadelphia, PA. For more information, please
visit www.carismatx.com.
Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements" within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to Carisma
Therapeutics' business, strategy, future operations, cash runway,
the advancement of Carisma Therapeutics' product candidates and
product pipeline, and clinical development of Carisma Therapeutics'
product candidates, including expectations regarding timing of
initiation and results of clinical trials, and participation by
Carisma Therapeutics in future healthcare industry and investor
conferences. The words "anticipate," "believe," "contemplate,"
"continue," "could," "estimate," "expect," "goals," "intend,"
"may," "might," "outlook," "plan," "project," "potential,"
"predict," "target," "possible," "will," "would," "could,"
"should," and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
Any forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. For a discussion of these risks
and uncertainties, and other important factors, any of which could
cause Carisma's actual results to differ from those contained in
the forward-looking statements, see the "Risk Factors" set forth in
the Company's Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on May
11, 2023, as well as discussions of potential risks,
uncertainties, and other important factors in Carisma's other
recent filings with the Securities and Exchange Commission. Any
forward-looking statements that are made in this press release
speak as of the date of this press release. Carisma undertakes no
obligation to revise the forward-looking statements or to update
them to reflect events or circumstances occurring after the date of
this press release, whether as a result of new information, future
developments or otherwise, except as required by the federal
securities laws.
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
Investor Contact:
investors@carismatx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-at-upcoming-healthcare-industry-conferences-in-september-2023-301908583.html
SOURCE Carisma Therapeutics Inc.